<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article303</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/KEYNOTE-024" style="display:block; margin-bottom:10px;">KEYNOTE-024 Original</a></li>
<h2><strong>KEYNOTE-024</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer". The New England Journal of Medicine. 2016. 375(19):1823-1833. PubMed • Full text • PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with previously untreated advanced non–small-cell lung cancer (NSCLC) with PD-L1 expression on at least 50% of tumor cells, how does pembrolizumab compare with platinum-based chemotherapy?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In previously untreated advanced NSCLC patients with PD-L1 expression on at least 50% of tumor cells, pembrolizumab significantly improved progression-free and overall survival with fewer adverse events compared to platinum-based chemotherapy.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
Advanced NSCLC patients with high PD-L1 expression often have limited treatment options beyond chemotherapy. Pembrolizumab, a PD-1 inhibitor, has shown promising results in such patients.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
This study may influence guidelines to consider pembrolizumab for first-line treatment in advanced NSCLC patients with PD-L1 expression on at least 50% of tumor cells.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Open-label, phase 3 randomized controlled trial.<br/>
N=305 patients.<br/>
Pembrolizumab vs. investigator's choice of platinum-based chemotherapy.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
305 patients with untreated, stage IV NSCLC with PD-L1 expression on ≥50% tumor cells.<br/>
Inclusion Criteria: Aged ≥18 years, ECOG performance-status score 0 or 1, and life expectancy ≥3 months. No sensitizing EGFR mutations or ALK translocations.<br/>
Exclusion Criteria: Systemic glucocorticoids or immunosuppressive treatment, untreated brain metastases, active autoimmune disease, interstitial lung disease, pneumonitis history.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Pembrolizumab (200 mg IV every 3 weeks for 35 cycles) vs. investigator's choice of platinum-based chemotherapy (4 to 6 cycles).<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome: Progression-free survival assessed by central radiologic review.<br/>
Secondary Outcomes: Overall survival, objective response rate, safety.<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
Open-label design could introduce bias. Low number of deaths and confounding effect of crossover design. Limited generalizability to patients with low PD-L1 expression.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
The trial was funded by Merck, the developer of pembrolizumab.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
Additional sources and research for further reading.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
